

# **Metro Brands**

Estimate change	1
TP change	1
Rating change	<b>( )</b>

Bloomberg	METROBRA IN
Equity Shares (m)	272
M.Cap.(INRb)/(USDb)	234.8 / 2.9
52-Week Range (INR)	980 / 446
1, 6, 12 Rel. Per (%)	5/37/43
12M Avg Val (INR M)	236

#### Financials & Valuations (INR b)

	10110		
Y/E March	FY23E	FY24E	FY25E
Sales	21.1	26.7	32.0
EBITDA	6.9	8.3	10.1
Adj. PAT	3.8	4.5	5.5
EBITDA Margin (%)	33.0	31.0	31.5
Adj. EPS (INR)	13.9	16.5	20.3
EPS Gr. (%)	77.9	19.1	23.3
BV/Sh. (INR)	60.5	75.7	94.5
Ratios			
Net D:E	0.1	(0.0)	(0.1)
RoE (%)	26.2	24.8	24.4
RoCE (%)	18.5	17.2	17.3
Payout (%)	9.5	9.5	9.5
Valuations			
P/E (x)	62.4	52.4	42.5
EV/EBITDA (x)	34.5	28.7	23.4
EV/Sales (X)	11.4	8.9	7.4
Div. Yield (%)	0.2	0.2	0.2
FCF Yield (%)	1.5	2.4	2.9

#### Shareholding pattern (%)

Sep-22	Dec-21
74.3	74.3
4.7	3.5
3.3	3.6
17.7	18.6
	74.3 4.7 3.3

FII Includes depository receipts

CMP: INR864 TP: INR1,050 (+22%) Buy

## Healthy performance in a weak environment

- Metro posted revenue growth of 24% YoY in 3QFY23, with strong store additions (48 stores) and healthy SSSG. PAT growth was soft at 12% YoY, despite high gross margin, due to aggressive store additions and marginal losses in Cravatex Brands post integration.
- We have largely maintained FY23/24 estimates as we have built in limited upside from FILA given its slow improvement in the next 2-4 quarters, though we are upbeat about it. We expect a revenue/PAT CAGR of 23%/21% over FY23-25. Metro's superlative store economics, healthy portfolio of products and strong balance sheet/FCF productivity warrant a rich valuation. We reiterate our Buy rating on the stock.

## Revenue/PAT up 24%/12% YoY (in line); 48 store adds

- Revenue increased 24% YoY to INR6b (in line), led by 14% growth in store additions; LTL growth in the mid-to-high single digits, partly through improved ASP.
- Gross profit increased 24% YoY to INR3.5b (in line). Gross margin inched up 10bp YoY to 59.2%, indicating the company's ability to pass on costs.
- Reported EBITDA rose 22% YoY to INR2b (in line) benefitting from operating leverage; however, margin declined by 40bp to 34.3% due to the CBL loss.
- PAT increased 12% YoY to INR1.1b (in line). The slowdown in PAT growth was due to a 41% increase in depreciation to INR480m (adjusting for CBL depreciation of INR20m). Margin declined 200bp to 18.8% in 3QFY23.
- Metro added 48 net stores (est. 21 stores), taking the total count to 720 stores, excluding 25 FILA stores. Metro will closely evaluate FILA stores' performance in the next 6-12 months.
- For 9MFY23, Revenue grew by 68% YoY while EBITDA/PAT grew 92%/2x.

### Key takeaways from management commentary

- Metro continued to witness healthy growth and, therefore, unlike its peers, Metro did not prepone EOSS. Growth could be attributed to a strong wedding/festive season, easing inflation pressure lately, a shift from unorganized to organized, and growing middle-class earnings.
- Management has maintained its target of 260 store additions by the end of FY25, excluding FitFlops's five store opening guidance and FILA.
- Management has also retained GM guidance of 55-57%. The delta between Pre- and Post-IndAS-116 EBITDA margin would be 8-9%. Hence, Pre-IndAS EBITDA margin would be 25-26%.
- For FILA, management plans to 1) clean old inventory (~INR500m cost), 2) reposition the brand and rationalize distribution, and 3) unlock value in FILA and Proline brands in India for sportswear and accessories.

Aliasgar Shakir - Research Analyst (Aliasgar.Shakir@motilaloswal.com)

### Valuation and view

Metro trades at rich valuations, backed by 1) internally funded growth because of a strong OCF-to-EBITDA ratio of over 50%, and 2) a balance sheet that is par excellence, with a healthy RoIC of 20% for FY22.

- The company has been consistently reporting healthy double-digit revenue/PAT growth for the last 10 years. We have factored in a revenue/ PAT CAGR of 23%/21% over FY23-25E, healthy store additions and strong SSSG. We have not built in significant growth from FILA.
- Currently, Cravatex is reporting losses; however, the company's ability to scale up small brands, particularly through the retail format, should be a key catalyst for growth.
- A combination of superior store economics and a strong runway of growth should allow Metro to garner rich valuations going ahead. We value the stock at 52x P/E on FY25E EPS to arrive at a TP of INR1,050. Reiterate our Buy rating on the stock.

Consolidated - Quarterly Earning												(INR m)
Y/E March		FY22				FY23E				FY23E	FY23E	Est
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	Var (%)
Revenue	1,314	3,246	4,838	4,032	5,080	4,763	5,987	5,226	13,429	21,055	5,805	3.1
YoY Change (%)	N.A	N.A	59.0	26.3	286.6	46.7	23.8	29.6	67.9	56.8	20.0	
Total Expenditure	1,168	2,278	3,159	2,733	3,251	3,292	3,935	3,640	9,338	14,118	3,802	3.5
EBITDA	146	968	1,679	1,298	1,829	1,472	2,052	1,586	4,092	6,938	2,003	2.4
EBITDA Margin (%)	11.1	29.8	34.7	32.2	36.0	30.9	34.3	30.3	30.5	33.0	34.5	0.2
Depreciation	315	336	344	347	390	414	504	408	1,342	1,716	419	20.4
Interest	113	123	123	145	134	148	173	269	504	724	168	2.5
Other Income	159	174	120	134	93	118	146	230	586	586	150	-2.7
PBT	-123	683	1,332	940	1,397	1,027	1,521	1,139	2,831	5,084	1,566	-2.9
Tax	-3	132	323	250	345	253	394	331	702	1,322	407	-3.3
Rate (%)	2.7	19.4	24.3	26.6	24.7	24.6	25.9	29.1	24.8	26.0	26.0	
Reported PAT	-120	551	1,009	690	1,052	774	1,128	808	2,130	3,762	1,159	-2.7
Adj PAT	-120	551	1,009	690	1,052	774	1,128	808	2,130	3,762	1,159	-2.7
YoY Change (%)	N.A	N.A	55	67	-979	41	12	17	227	76.7	15	

E: MOFSL Estimates

**Exhibit 1: Valuation based on FY25E** 

Particulars	INR/Share
EPS	20
Target PE (x)	52
Equity value/share (INR)	1,050
Upside/(Downside) (%)	22%
CMP (INR)	864

Source: MOFSL, Company

## **Cravatex brands (CBL) update**

- CBL contributed INR90m in revenue with gross margin of 47% (vs Metro's 59% GM).
- Currently, CBL is reporting an EBITDA loss of INR20m with EBITDAM of -19% (vs 34% EBITDAM of Metro).
- To curb losses, in the next six months, management will be prioritizing:
- Integration with Metro brands' ecosystem to leverage costs and operation synergies
- Focus on the liquidation of current excess inventory (INR500m valued at cost) and the improvement of the cash conversion cycle
- Evaluate means to improve sales throughput at all existing sales channels (i.e. EBO's / LFS etc.)
- CBL has 25 FILA EBOs (in addition to existing 720 stores). Metro will closely evaluate the stores' performance in the next 6-12 months.
- Metro has taken only three brands from Cravatex—FILA, Proline and Vans. It will focus on FILA and Proline first to unlock value in the sportswear and accessories segment.
- Metro have funded INR1.15b in CBL, of which INR1.060b was used to repay existing debt. Recently, Metro infused INR80m for working capital requirement. The company expects that the WC mismatch should get addressed in 3-4 months; it is a long-term endeavor of management that the WC is funded independently.
- Metro also expects CBL's long-term gross and PAT margins to be in line with the current margins of the five existing brands.



## Key takeaways from management interaction

## **Key highlights**

- Metro continued to witness healthy growth and, therefore, unlike its peers, Metro did not prepone EOSS. Growth could be attributed to a strong wedding/ festive season, easing inflation pressure lately, a shift from unorganized to organized and growing middle-class earnings.
- Management has maintained its target of 260 store additions by the end of FY25, excluding FitFlops's five store opening guidance and FILA.
- Management has also retained GM guidance of 55-57%. The delta between Preand Post-IndAS-116 EBITDA margin would be 8-9%. Hence, Pre-IndAS EBITDA margin would be 25-26%.
- For FILA, Metro plans to 1) clean old inventory (~INR500m at cost), 2) reposition the brand and rationalize distribution, and 3) unlock value in FILA and Proline brands in India for sportswear and accessories.

#### **Detailed notes**

### Stores addition

- Metro opened the highest number stores in 3Q, taking the total count to 720 stores. The city count increased by six cities to 164 cities. Metro tends to pick the best real estate location. The store addition was within the guidance of 240-260 stores (excluding Fitflop) by the end of FY25. The company follows the cluster approach to grow.
- > Cluster strategy—leveraging the existing supply chain, distributors, etc. The company can leverage all seven brands (including FILA and Proline) to grow.
- New geography strategy—this is another strategy of the company to grow its stores simultaneously.
- The company is attracting customers, as it has the best operational rigor and is flexible to change as per customer needs. Moreover, the large untapped market is supporting good footfalls.
- Generally, new stores have higher SSG for the first 2-3 years.
- Only nine stores are franchise stores and the rest 711 stores are companyowned; a majority of them are on lease.

#### **Demand outlook**

- Strong growth was driven by a strong wedding/festive season, growth of middle-class earnings, easing in inflation pressure/supply chain issues, and a shift from unorganized to organized.
- Management remained optimistic about the demand outlook. There was no erosion in demand in Dec'22; however, in Nov'22, there was some erosion in some regions.
- Unlike other retailers, Metro did not start EOSS. It started EOSS as usual in the Jan'23 second week.
- Metro is strictly pursuing its strategic initiatives, such as 1) premiumisation, 2) new store additions, 3) gross margin stabilization, and 4) revenue/profitability within guidance.
- The company believes that Tier 2 and Tier 3 cities have a lot of growth potential.
- Metro saw some weakness in the mass-market brand, Walkaway.

#### **Financials**

- Revenue for 9MFY23 grew 66% on pre-Covid (vs 9MFY20). Store additions grew by 34-35%, suggesting a balance of 30% from LTL growth (10% annually).
- High depreciation was due to the lease accounting 116AS adjustment as a higher number of stores were opened in 9MFY23 (the impact was INR200m). For the first six months of the store opening, depreciation remains higher.
- The ASP grew 3-4% YoY (including accessories); it was up 6-7% YoY for footwear. The increase in ASP was led by inflation and was mix-adjusted.
- The ASP was INR1,450 for 9MFY23 and INR1,510 for 3QFY23. Excluding accessories, the ASP was INR2,000. Accessories are a high-GM business with a starting ASP of INR299.
- INR3,000+ ASP products show more growth than others.
- Management has maintained the GM guidance of 55-57%.
- The delta between Pre- and Post-IndAS 116 EBITDA margin would be 8-9%. The Post IndAS EBITDA margin would be 25-26%.

**Exhibit 2: Quarterly performance** 

	3QFY22	2QFY23	3QFY23	YoY%	QoQ%	3QFY23E	v/s Est (%)	3QFY23*	YoY%
Total Revenue	4,838	4,763	5,987	24	26	5,805	3	5,897	22
Raw Material cost	1,978	2,032	2,441	23	20	2,409	1		
Gross Profit	2,860	2,732	3,546	24	30	3,396	4	3,506	23
Gross margin (%)	59.1	57.3	59.2	10	188	58.5	73	59.5	33
Employee Costs	333	428	496	49	16	464	7		
SGA Expenses	848	832	998	18	20	929	7		
EBITDA	1,679	1,472	2,052	22	39	2,003	2	2,072	23
EBITDA margin (%)	34.7	30.9	34.3	-44	337	34.5	-23.1	35	43
Depreciation and amortization	344	414	504	47	22	419	20	484	41%
EBIT	1,335	1,058	1,548	16	46	1,584	-2	1588	19%
EBIT margin (%)	27.6	22.2	25.8	-175	365	27.3	-144	27	-68
Finance Costs	123	148	173	40	16	168	3		
Other income	120	118	146	22	24	150	-3		
Exceptional item	0	0	0	NM	NM	0	NM		
Profit before Tax	1,332	1,027	1,521	14	48	1,566	-3		
Tax	323	253	394	22	56	407	-3		
Tax rate (%)	24.3	24.6	25.9	158.8	127.6	26.0	NM		
Profit after Tax	1,009	774	1,128	12	46	1,159	-3	1168	16%
Adj Profit after Tax	1,009	774	1,128	12	46	1,159	-3	1168	
PAT margin (%)	20.8	16.3	18.8	-201.3	258.0	20.0	-113	19.8	-105
*Consol P&L excluding CBL loss									

Source: MOFSL, Company


**Exhibit 3: Summary of changes in our estimates** 

.5		
FY23E	FY24E	FY25E
20,915	25,022	29,178
21,055	26,700	31,979
0.7	6.7	9.6
6,954	8,170	9,614
6,938	8,277	10,074
-0.2	1.3	4.8
33.3	32.7	33.0
33.0	31.0	31.5
-30	-165	-145
3,869	4,550	5,393
3,762	4,481	5,523
-2.8	-1.5	2.4
14.3	16.8	19.9
13.9	16.5	20.3
-2.8	-1.5	2.4
	20,915 21,055 0.7 6,954 6,938 -0.2 33.3 33.0 -30 3,869 3,762 -2.8	FY23E         FY24E           20,915         25,022           21,055         26,700           0.7         6.7           6,954         8,170           6,938         8,277           -0.2         1.3           33.3         32.7           33.0         31.0           -30         -165           3,762         4,481           -2.8         -1.5           14.3         16.8           13.9         16.5

Source: MOFSL, Company


## **Story in charts**

Exhibit 4: Revenue up 24% YoY, store adds up 14% YoY




Source: MOFSL, Company

Exhibit 5: GP up 24% YoY, in line with revenue




Source: MOFSL, Company

Exhibit 6: EBITDA up 22% YoY, margin down 40bp due to CBL loss



Source: MOFSL, Company

Exhibit 7: PAT growth slowed to 12% YoY due to CBL loss and depreciation




Source: MOFSL, Company

Exhibit 8: 48 new store adds vs 48 adds in 1HFY23



Source: MOFSL, Company

Exhibit 9: Expect volume growth to drive revenue growth




Source: MOFSL, Company

Exhibit 10: Expect revenue to grow 23% over FY23-25

#### Revenues (INR b) ── Growth YoY (%) 67.9 56.8 26.8 19.8 19.2 13.4 12.1 5.6 10.9 12.9 13.4 9.1 12.2 21.1 26.7 32.0 FY20


Source: MOFSL, Company

Exhibit 11: Expect GP to grow in line with revenue of 22%




Source: MOFSL, Company

Exhibit 12: Expect EBITDA to grow 20% over FY23-25E




Source: MOFSL, Company

Exhibit 13: Expect pre-IndAS EBITDA to grow 21% over FY23-25




Source: MOFSL, Company

Exhibit 14: Expect 21% PAT CAGR over FY23-25E



Source: MOFSL, Company

**Exhibit 15: Format-wise store counts** 



Source: MOFSL, Company

# **Financials and valuations**

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Total Income from Operations	8,031	9,103	10,853	12,171	12,852	8,001	13,429	21,055	26,700	31,979
Change (%)	NA	13.4	19.2	12.1	5.6	-37.7	67.9	56.8	26.8	19.8
Raw Materials	3,902	4,391	4,759	5,487	5,707	3,605	5,659	8,801	11,481	13,751
Gross Profit	4,129	4,712	6,094	6,683	7,145	4,396	7,770	12,254	15,219	18,228
Margin (%)	51.4	51.8	56.2	54.9	55.6	54.9	57.9	58.2	57.0	57.0
Employees Cost	695	830	975	1,121	1,268	1,026	1,212	1,842	2,216	2,558
Other Expenses	2,011	2,337	2,860	2,204	2,351	1,655	2,466	3,474	4,726	5,596
Total Expenditure	6,608	7,558	8,594	8,813	9,325	6,285	9,338	14,118	18,423	21,906
% of Sales	82.3	83.0	79.2	72.4	72.6	78.6	69.5	67.1	69.0	68.5
EBITDA	1,423	1,545	2,259	3,358	3,527	1,715	4,092	6,938	8,277	10,074
Margin (%)	17.7	17.0	20.8	27.6	27.4	21.4	30.5	33.0	31.0	31.5
Depreciation	130	161	195	936	1,206	1,218	1,342	1,716	2,027	2,416
EBIT	1,293	1,384	2,064	2,422	2,321	497	2,749	5,222	6,250	7,658
Int. and Finance Charges	7	4	4	339	395	437	504	724	840	968
Other Income	46	65	89	198	259	785	586	586	645	774
PBT bef. EO Exp.	1,332	1,444	2,149	2,281	2,184	845	2,831	5,084	6,056	7,464
EO Items	0	0	0	0	0	0	0	0	0	0
PBT after EO Exp.	1,332	1,444	2,149	2,281	2,184	845	2,831	5,084	6,056	7,464
Total Tax	458	499	730	769	587	193	702	1,322	1,574	1,941
Tax Rate (%)	34.4	34.5	34.0	33.7	26.9	22.8	24.8	26.0	26.0	26.0
Minority Interest	0	0	0	15	8	-6	15	0	0	0
Reported PAT	874	946	1,418	1,497	1,589	658	2,115	3,762	4,481	5,523
Adjusted PAT	874	946	1,418	1,497	1,589	658	2,115	3,762	4,481	5,523
Change (%)	-261.3	8.2	50.0	5.5	6.2	-58.6	221.3	77.9	19.1	23.3
Margin (%)	10.9	10.4	13.1	12.3	12.4	8.2	15.7	17.9	16.8	17.3
Consolidated - Balance Sheet										(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Equity Share Capital	147	147	147	1,328	1,328	1,328	1,358	1,358	1,358	1,358
Total Reserves	3,817	4,532	5,624	5,366	6,980	7,147	11,289	14,694	18,750	23,748
Net Worth	3,964	4,679	5,771	6,694	8,308	8,474	12,647	16,052	20,107	25,106
Minority Interest	83	114	146	0	0	0	224	224	224	224

Consolidated - Balance Sheet										(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Equity Share Capital	147	147	147	1,328	1,328	1,328	1,358	1,358	1,358	1,358
Total Reserves	3,817	4,532	5,624	5,366	6,980	7,147	11,289	14,694	18,750	23,748
Net Worth	3,964	4,679	5,771	6,694	8,308	8,474	12,647	16,052	20,107	25,106
Minority Interest	83	114	146	0	0	0	224	224	224	224
Total Loans	30	29	60	4,244	5,491	5,669	6,922	10,744	12,445	14,367
Lease Liabilities				4,146	5,376	5,655	6,922	10,744	12,445	14,367
Deferred Tax Liabilities	2	17	23	0	0	0	0	0	0	0
Other Liabilities	40	51	61	6	6	6	6	6	6	6
Capital Employed	4,119	4,889	6,061	10,944	13,804	14,150	19,800	27,027	32,783	39,704
Gross Block	0	0	0	7,566	9,798	10,394	12,765	18,436	22,101	26,219
Less: Accum. Deprn.	0	0	0	1,636	2,718	3,158	4,287	6,003	8,030	10,446
Net Fixed Assets	1,345	1,713	1,846	5,930	7,080	7,236	8,478	12,433	14,070	15,773
Other Non-Current	0	0	0	381	444	493	614	614	614	614
Capital WIP	6	43	60	41	130	45	62	62	62	62
Total Investments	1,066	1,297	2,274	2,099	3,484	3,997	3,625	3,625	3,625	3,625
Curr. Assets, Loans&Adv.	2,781	3,382	3,539	4,624	4,912	4,655	10,140	13,646	18,838	24,787
Inventory	2,326	2,646	2,794	3,646	3,761	2,898	4,242	5,546	7,235	8,665
Account Receivables	236	303	394	519	701	506	577	865	1,024	1,227
Cash and Bank Balance	65	250	154	121	109	879	4,350	6,176	9,543	13,859
Loans and Advances	153	183	197	338	341	373	971	1,059	1,036	1,036
Curr. Liability & Prov.	1,078	1,547	1,658	2,271	2,370	2,444	3,342	3,577	4,650	5,381
Account Payables	873	1,077	1,413	1,939	2,015	2,047	2,343	3,135	4,089	4,709
Other Current Liabilities	187	455	187	307	331	389	958	421	534	640
Provisions	18	15	58	25	25	8	40	21	27	32
Net Current Assets	1,702	1,835	1,881	2,353	2,542	2,212	6,798	10,069	14,188	19,406
Deferred Tax assets	0	0	0	141	124	167	223	223	223	223
Appl. of Funds	4,119	4,889	6,061	10,944	13,804	14,150	19,800	27,027	32,783	39,704

# **Financials and valuations**

Ratios										
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Basic (INR)	1110	11117	1110	1113	1120	1121	1122	TTZJL	11246	11232
EPS EPS	29.7	32.1	48.2	5.6	6.0	2.5	7.8	13.9	16.5	20.3
Cash EPS	34.1	37.6	54.8	9.2	10.5	7.1	13.0	20.6	24.5	29.9
BV/Share	134.6	158.8	195.9	25.2	31.3	31.9	47.6	60.5	75.7	94.5
DPS	0.0	0.0	0.0	3.5	3.0	1.1	0.8	1.3	1.6	1.9
	0.0	0.0	0.0							
Payout (%)	0.0	0.0	0.0	31.0	25.1	45.4	9.6	9.5	9.5	9.5
Valuation (x)		26.0	10.0	152.5	1446	240.0	111.0	62.4	F2 4	42.5
P/E		26.9	18.0	153.5	144.6	349.0	111.0	62.4	52.4	42.5
Cash P/E		23.0	15.8	94.4	82.2	122.4	66.4	41.9	35.3	28.9
P/BV		5.4	4.4	34.3	27.6	27.1	18.2	14.3	11.4	9.1
EV/Sales		2.8	2.3	9.8	9.4	29.3	17.7	11.4	8.9	7.4
EV/EBITDA		16.3	11.2	35.4	34.1	136.7	58.0	34.5	28.7	23.4
Dividend Yield (%)	0.0	0.0	0.0	0.4	0.3	0.1	0.1	0.2	0.2	0.2
FCF per share	21.7	8.8	41.2	10.3	17.3	9.0	8.6	13.4	20.3	25.1
Return Ratios (%)										
RoE	44.1	21.9	27.1	24.0	21.2	7.8	20.0	26.2	24.8	24.4
RoCE	44.0	21.8	27.0	20.7	15.3	7.1	14.9	18.5	17.2	17.3
RoIC	56.9	28.9	39.7	26.2	18.1	4.0	19.7	26.7	25.2	27.2
Working Capital Ratios										
Fixed Asset Turnover (x)	NA	NA	NA	1.6	1.3	0.8	1.1	1.1	1.2	1.2
Asset Turnover (x)	1.9	1.9	1.8	1.1	0.9	0.6	0.7	0.8	0.8	0.8
Inventory (Days)	218	220	214	243	241	293	274	230	230	230
Debtor (Days)	11	12	13	16	20	23	16	15	14	14
Creditor (Days)	82	90	108	129	129	207	151	130	130	125
Leverage Ratio (x)										
Current Ratio	2.6	2.2	2.1	2.0	2.1	1.9	3.0	3.8	4.1	4.6
Interest Cover Ratio	189.8	309.9	504.0	7.2	5.9	1.1	5.5	7.2	7.4	7.9
Net Debt/Equity	-0.3	-0.3	-0.4	0.3	0.2	0.1	-0.1	0.1	0.0	-0.1
Consolidated - Cash Flow Staten									_	(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
OP/(Loss) before Tax	1,332	1,484	2,149	2,281	2,184	845	2,831	5,084	6,056	7,464
Depreciation	130	160	195	936	1,206	1,218	1,342	1,716	2,027	2,416
Interest & Finance Charges	7	4	5	339	395	437	491	724	840	968
Direct Taxes Paid	-445	-497	-682	-803	-608	-204	-715	-1,322	-1,574	-1,941
(Inc)/Dec in WC	-100	-138	47	-570	-156	1,135	-638	-1,445	-752	-902
CF from Operations	924	1,013	1,713	2,183	3,021	3,432	3,312	4,758	6,595	8,005
Others	-25	-170	-167	-227	-291	-779	-491	-586	-645	-774
CF from Operating incl EO	898	843	1,546	1,957	2,731	2,653	2,821	4,171	5,950	7,231
(Inc)/Dec in FA	-258	-583	-331	-584	-440	-251	-479	-520	-427	-424
Free Cash Flow	640	260	1,215	1,373	2,291	2,402	2,342	3,651	5,523	6,807
(Pur)/Sale of Investments	-376	-92	-853	-140	-1,243	-329	538	0	0	0
Others	10	-178	247	51	57	-644	68	586	645	774
CF from Investments	-625	-853	-937	-673	-1,626	-1,224	127	66	218	350
Issue of Shares	2	0	0	7	0	0	2,924	0	0	0
Inc/(Dec) in Debt	-53	-1	31	39	17	-101	-14	0	0	0
Interest Paid	-7	-4	-5	-6	-8	-6	-1	-724	-840	-968
interest i ala		0	-532	-446	0	-498	0	-357	-426	-524
Repayment of loan	-222	U		-						
	-222 0	0	0	-913	-1,124	-665	-1,/44	-1,329	-1,536	-1,//2
Repayment of loan Others	0	0	0	-913 <b>-1.320</b>	-1,124 - <b>1.115</b>		-1,744 <b>1.164</b>	-1,329 - <b>2.410</b>	-1,536 - <b>2.802</b>	
Repayment of loan Others CF from Fin. Activity	0 - <b>279</b>	0 -5	0 - <b>505</b>	-1,320	-1,115	-1,271	1,164	-2,410	-2,802	-3,265
Repayment of loan Others CF from Fin. Activity Inc/Dec of Cash	0 - <b>279</b> -6	0 -5 -15	0 - <b>505</b> <b>104</b>	-1,320 -37	-1,115 -10	-1,271 158	1,164 4,112	-2,410 1,827	-2,802 3,367	-3,265 4,316
Repayment of loan Others CF from Fin. Activity Inc/Dec of Cash Opening Balance	0 - <b>279</b> - <b>6</b> 69	0 -5 -15 63	0 - <b>505</b> <b>104</b> 48	- <b>1,320</b> - <b>37</b> 152	-1,115 -10 115	-1,271 158 105	1,164 4,112 263	- <b>2,410 1,827</b> 4,375	-2,802 3,367 6,202	- <b>3,265 4,316</b> 9,569
Repayment of loan Others CF from Fin. Activity Inc/Dec of Cash Opening Balance Closing Balance	0 -279 -6 69 63	0 -5 -15 63 48	0 -505 104 48 152	-1,320 -37 152 115	-1,115 -10 115 105	-1,271 158 105 263	1,164 4,112 263 4,375	-2,410 1,827 4,375 6,202	-2,802 3,367 6,202 9,569	-3,265 4,316 9,569 13,885
Repayment of loan Others CF from Fin. Activity Inc/Dec of Cash Opening Balance	0 - <b>279</b> - <b>6</b> 69	0 -5 -15 63	0 - <b>505</b> <b>104</b> 48	- <b>1,320</b> - <b>37</b> 152	-1,115 -10 115	-1,271 158 105	1,164 4,112 263	- <b>2,410 1,827</b> 4,375	-2,802 3,367 6,202	-1,772 -3,265 4,316 9,569 13,885 -26 13,859

## $\mathsf{NOTES}$

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	<-10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at

http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at <a href="https://www.nseindia.com">www.nseindia.com</a>, <a href="https://www.nseindia.com">www.nseindia.com</a>, <a href="https://www.nseindia.com">www.nseindia.com</a>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated. from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered brokerdealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
  MOFSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

18 January 2023 11

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however, the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; <a href="https://www.motilaloswal.com">www.motilaloswal.com</a>. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: <a href="mailto:na@motilaloswal.com">na@motilaloswal.com</a>, Contact No: 022-71881085.

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL: IN-DP-16-2015; NSDL: IN-DP-NSDL-152-2000; Research Analyst: INH000000412. AMFI: ARN.: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.